Ethylene Glycol

Ethylene Glycol

SCHEMBL1639873

Cc1ccccc1S(=O)(=O)O.Cc1ccccc1S(=O)(=O)O.OCCO

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.47
RAPGEF4 Q8WZA2 1/20 0.45
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
GAA P10253 2/20 0.42
KMT2A Q03164 2/20 0.41
HCRTR2 O43614 1/20 0.40
SUMO2 P61956 1/20 0.40
SUMO1 P63165 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP3 Q9H4L4 1/20 0.40
SENP2 Q9HC62 1/20 0.40
SENP1 Q9P0U3 1/20 0.40
HSD11B1 P28845 1/20 0.39
MEN1 O00255 1/20 0.38
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene Glycol SCHEMBL15653006 1.00 MYC (0.47) MYCRAPGEF4ALDH1A1KDM4EHPGD
1,3-Propanediol SCHEMBL1502277 0.92 MYC (0.44) MYCRAPGEF4ALDH1A1KDM4EHPGD
Alcohol SCHEMBL27960969 0.92 RAPGEF4 (0.49) MYCRAPGEF4ALDH1A1KDM4EHPGD
SCHEMBL29392580 0.91 MYC (0.53) MYCRAPGEF4ALDH1A1KDM4EGAA
SCHEMBL1748 0.91 MYC (0.53) MYCRAPGEF4ALDH1A1KDM4EGAA
Monoethanolamine SCHEMBL8423206 0.90 MYC (0.43) MYCRAPGEF4ALDH1A1KDM4EHPGD
Alcohol SCHEMBL28156310 0.90 RAPGEF4 (0.47) MYCRAPGEF4ALDH1A1KDM4EHPGD
SCHEMBL6916771 0.89 MYC (0.52) MYCRAPGEF4ALDH1A1KDM4EGAA
SCHEMBL948871 0.89 MYC (0.52) MYCRAPGEF4ALDH1A1KDM4EGAA
Ammonia Solution, Strong SCHEMBL6360239 0.89 MYC (0.52) MYCRAPGEF4ALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116209723-A Desalination of water using complexing agents attached to magnetic nanoparticles NWPT-纳米净水科技有限公司 2023-06-02 CN disclosed
CN-114514303-A Liquid crystal aligning agent for vertical alignment, liquid crystal alignment film, and liquid crystal display element 日产化学株式会社 2022-05-17 CN disclosed
CN-110914270-B Preparation method of pirlindole enantiomer and salt thereof 社会医疗技术员技术股份公司 2022-05-03 CN disclosed
CN-110871039-B Salt tolerant anion exchange media 帕尔公司 2022-02-08 CN disclosed
CN-112969959-A Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element 日产化学株式会社 2021-06-15 CN disclosed
CN-112912792-A Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element using same 日产化学株式会社 2021-06-04 CN disclosed
CN-106986748-B Oligofluorenediols, oligofluorenediaryl esters, and methods for producing these 三菱化学株式会社 2020-10-09 CN disclosed
CN-110914270-A Preparation method of pirlindole enantiomer and salt thereof 社会医疗技术员技术股份公司 2020-03-24 CN disclosed
CN-110871039-A Salt tolerant anion exchange media 帕尔公司 2020-03-10 CN disclosed
US-20110097269-A1 PHENYLOXYANILINE DERIVATIVES LEHMANN LUTZ 2011-04-28 US disclosed
US-7803960-B2 Phenyloxyaniline derivatives BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-09-28 US disclosed
CN-101535241-A Phenyloxyaniline derivatives BAYER SCHERING PHARMA AG (DE) 2009-09-16 CN disclosed
EP-2064176-A1 PHENYLOXYANILINE DERIVATIVES Bayer Schering Pharma Aktiengesellschaft (DE) 2009-06-03 EP disclosed
US-20080177108-A1 Phenyloxyaniline derivatives BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-07-24 US disclosed
WO-2008028533-A1 PHENYLOXYANILINE DERIVATIVES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-13 WO disclosed
EP-1894915-A1 Phenyloxyaniline derivatives Bayer Schering Pharma Aktiengesellschaft (DE) 2008-03-05 EP disclosed
US-6312882-B1 PRECIPITATING SILVER HALIDE IN A PROTECTIVE COLLOIDAL SILICA, CONTROLLING NUCLEATION, SUBJECTING TO PHYSICAL RIPENING, DESALTING, CHEMICAL RIPENING AGFA-GEVAERT (BE) 2001-11-06 US disclosed
EP-0602254-B1 POLYMERIZABLE MONOMER, POLYMER THEREOF, AND PROCESS FOR PRODUCING THE SAME OTSUKA KAGAKU KK (JP) 1997-01-02 EP disclosed
US-5476913-A Bactericides OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1995-12-19 US disclosed
EP-0602254-A1 POLYMERIZABLE MONOMER, POLYMER THEREOF, AND PROCESS FOR PRODUCING THE SAME OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1994-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110097269-A1 PHENYLOXYANILINE DERIVATIVES PNMT, PAH, NAT1 MYC 821/4885RAPGEF4 1044/4885ALDH1A1 430/4885
US-20080177108-A1 Phenyloxyaniline derivatives PNMT, PAH, NAT1 MYC 821/4885RAPGEF4 1044/4885ALDH1A1 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.